Trial · NCT03117309
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 15 of 15
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 1-year Progression Free Survival (PFS) Rate for ccRCC Patients | Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC | PD-L1 0% | 34.6 | 95% Confidence Interval 24.3 to 45.1 | Percentage of participants |
| 1-year Progression Free Survival (PFS) Rate for ccRCC Patients | Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC | PD-L1 1-5% | 53.8 | 95% Confidence Interval 24.8 to 76.0 | Percentage of participants |
| 1-year Progression Free Survival (PFS) Rate for ccRCC Patients | Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC | PD-L1 5-20% | 33.3 | 95% Confidence Interval 0.9 to 77.4 | Percentage of participants |
| 1-year Progression Free Survival (PFS) Rate for ccRCC Patients | Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC | PD-L1 > 20% | 75 | 95% Confidence Interval 31.5 to 93.1 | Percentage of participants |
| Objective Response Rate for ccRCC Patients Treated With Nivolumab Monotherapy | Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC | PD-L1 0% | 26.9 | 95% Confidence Interval 17.5 to 38.2 | Percentage of participants |
| Objective Response Rate for ccRCC Patients Treated With Nivolumab Monotherapy | Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC | PD-L1 1-5% | 53.8 | 95% Confidence Interval 25.1 to 80.8 | Percentage of participants |
| Objective Response Rate for ccRCC Patients Treated With Nivolumab Monotherapy | Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC | PD-L1 5-20% | 33.3 | 95% Confidence Interval 0.8 to 90.6 | Percentage of participants |
| Objective Response Rate for ccRCC Patients Treated With Nivolumab Monotherapy | Cohort A Part A: Nivolumab Monotherapy in Clear Cell RCC | PD-L1 > 20% | 75 | 95% Confidence Interval 34.9 to 96.8 | Percentage of participants |
| Objective Response Rate (ORR) for ccRCC Patients Treated With Nivolumab and Ipilimumab | Cohort A Part B: Nivolumab and Ipilimumab in Clear Cell RCC | PD-L1 0% | 7.7 | 95% Confidence Interval 0.9 to 25.1 | Percentage of participants |
| Objective Response Rate (ORR) for ccRCC Patients Treated With Nivolumab and Ipilimumab | Cohort A Part B: Nivolumab and Ipilimumab in Clear Cell RCC | PD-L1 1-5% | 66.7 | 95% Confidence Interval 9.4 to 99.2 | Percentage of participants |
| Objective Response Rate (ORR) for ccRCC Patients Treated With Nivolumab and Ipilimumab | Cohort A Part B: Nivolumab and Ipilimumab in Clear Cell RCC | PD-L1 5-20% | 0 | 95% Confidence Interval NA to NA | Percentage of participants |
| Clinical Activity for nccRCC Patients | Cohort B Part A: Nivolumab Monotherapy in Non Clear Cell RCC | 60 | Percentage of participants | ||
| 1-year Progression Free Survival (PFS) Rate for nccRCC Patients | Cohort B Part A: Nivolumab Monotherapy in Non Clear Cell RCC | 25.4 | 95% Confidence Interval 14.3 to 45 | Percentage of participants | |
| Number of Participants With Adverse Events | Cohort A: Nivolumab and Salvage Nivolumab/Ipilimumab in Clear Cell RCC | 128 | Participants | ||
| Number of Participants With Adverse Events | Cohort B: Nivolumab and Salvage Nivolumab/Ipilimumab in Non-clear Cell RCC | 35 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03117309/results